SGStefanie Groeneveld-Krentz

Stefanie Groeneveld-Krentz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Stefanie Groeneveld-Krentz has a total of 200 co-authors. Here are the top co-authors by number of shared publications:

  • Renate Kirschner-Schwabe

    Department of Pediatric Oncology/Hematology, Charité Universitätsmedizin Berlin, Berlin, Germany

    9 shared publications
  • Arend von Stackelberg

    Department of Pediatric Oncology Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany

    8 shared publications
  • Cornelia Eckert

    Department of Pediatric Oncology and Hematology, Charité—University Medical Center Berlin, Berlin, Germany

    7 shared publications
  • Jana Hof

    Department of Pediatric Oncology/Hematology, Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin–Berlin Institute of Health, Berlin, Germany

    5 shared publications
  • Leonid Karawajew

    Department of Paediatric Oncology/Hematology, Charité Universitätsmedizin Berlin, Berlin, Germany

    5 shared publications
  • Andishe Attarbaschi

    St Anna Children's Research Institute and Children's Hospital, Medical University of Vienna, Vienna, Austria

    4 shared publications

Latest Publications

  • Open Access

    Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials

    by Cornelia Eckert, Catriona Parker, Anthony V. Moorman, Julie Ae. Irving, Renate Kirschner-Schwabe, Stefanie Groeneveld-Krentz, Tamas Révész, Peter Hoogerbrugge, Jeremy Hancock, Rosemary Sutton, et al.


  • Open Access

    HLA-E expression constitutes a novel determinant for ALL disease monitoring following hematopoietic stem cell transplantation

    by Sarah B. Reusing, Angela R. Manser, Stefanie Groeneveld-Krentz, Vera Rebmann, Peter A. Horn, Roland Meisel, Leonid Karawajew, Arndt Borkhardt, Markus Uhrberg, Florian Babor


  • Open Access

    Clinical and genetic characteristics of children with acute lymphoblastic leukemia and Li–Fraumeni syndrome

    by Greta Winter, Renate Kirschner-Schwabe, Stefanie Groeneveld-Krentz, Gabriele Escherich, Anja Möricke, Arend von Stackelberg, Martin Stanulla, Simon Bailey, Lisa Richter, Doris Steinemann, et al.


  • Open Access

    Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia

    by Malwine J. Barz, Jana Hof, Stefanie Groeneveld-Krentz, Jui Wan Loh, Annabell Szymansky, Kathy Astrahantseff, Arend von Stackelberg, Hossein Khiabanian, Adolfo A. Ferrando, Cornelia Eckert, et al.

    Activating mutations in cytosolic 5′-nucleotidase II (NT5C2) are considered to drive relapse formation in acute lymphoblastic leukemia (ALL) by conferring purine analog resistance. To examine the clinical effects of NT5C2 mutations in relapsed ALL, we analyzed NT5C2 in 455 relapsed B-cell precursor ALL patients treated within the ALL-REZ BFM 2002 relapse trial using sequencing and sensitive allele-specific real-time polymerase chain reaction. We detected 110 NT5C2 mutations in 75 (16.5%) of 455 B-cell precursor ALL relapses. Two-thirds of relapses harbored subclonal mutations and only one-third harbored clonal mutations. Event-free survival after relapse was inferior in patients with relapses with clonal and subclonal NT5C2 mutations compared with those without (19% and 25% vs 53%, P < .001). However, subclonal, but not clonal, NT5C2 mutations were associated with reduced event-free survival in multivariable analysis (hazard ratio, 1.89; 95% confidence interval, 1.28-2.69; P = .001) and with an increased rate of nonresponse to relapse treatment (subclonal 32%, clonal 12%, wild type 9%, P < .001). Nevertheless, 27 (82%) of 33 subclonal NT5C2 mutations became undetectable at the time of nonresponse or second relapse, and in 10 (71%) of 14 patients subclonal NT5C2 mutations were undetectable already after relapse induction treatment. These results show that subclonal NT5C2 mutations define relapses associated with high risk of treatment failure in patients and at the same time emphasize that their role in outcome is complex and goes beyond mutant NT5C2 acting as a targetable driver during relapse progression. Sensitive, prospective identification of NT5C2 mutations is warranted to improve the understanding and treatment of this aggressive ALL relapse subtype.


  • Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics

    by Cornelia Eckert, Stefanie Groeneveld-Krentz, Renate Kirschner-Schwabe, Nikola Hagedorn, Christiane Chen-Santel, Peter Bader, Arndt Borkhardt, Gunnar Cario, Gabriele Escherich, Renate Panzer-Grümayer, et al.

    PURPOSE: Minimal residual disease (MRD) helps to accurately assess when children with late bone marrow relapses of B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) will benefit from allogeneic hematopoietic stem-cell transplantation (allo-HSCT). More detailed dissection of MRD response heterogeneity and the specific genetic aberrations could improve current practice. PATIENTS AND METHODS: MRD was assessed after induction treatment and at different times during relapse treatment until allo-HSCT (indicated in poor responders to induction; MRD ≥ 10−3) for patients being treated for late BCP-ALL bone marrow relapses (n = 413; median follow-up, 9.4 years) in the ALL-REZ BFM 2002 trial/registry (ClinicalTrials.gov identifier: NCT00114348 ). RESULTS: Patients with both good (MRD < 10−3) and poor responses to induction treatment reached excellent event-free survival (EFS; 72% v 65%) and overall survival (OS; 82% v 74%). Patients with MRD of 10−2 or greater after induction had reduced EFS (56%), and their MRD persisted until allo-HSCT more frequently than it did in patients with MRD of 10−3 or greater to less than 10−2 ( P = .037). Patients with 25% or more leukemic blasts after induction (early nonresponders) had the poorest prognosis (EFS, 22%). Interestingly, patients with MRD of 10−3 or greater before allo-HSCT (late nonresponders) still had an EFS of 50% and OS of 63%, which in principle justifies allo-HSCT in these patients. From a panel of selected candidate genes, TP53 alterations (frequency, 8%) were the only genetic alteration with independent prognostic value in any MRD-based response subgroup. CONCLUSION: After induction treatment, MRD-based treatment stratification resulted in excellent survival in patients with late relapsed BCP-ALL. Prognosis could be further improved in very poor responders by intensifying treatment directly after induction. TP53 alterations can be defined as a novel genetic high-risk marker in all MRD response groups in late relapsed BCP-ALL. Here we identified early and late nonresponders to be considered as events in future trials.


  • Open Access

    Reflection of neuroblastoma intratumor heterogeneity in the new OHC‐NB1 disease model

    by Theresa M. Thole, Joern Toedling, Annika Sprüssel, Sebastian Pfeil, Larissa Savelyeva, David Capper, Clemens Messerschmidt, Dieter Beule, Stefanie Groeneveld‐Krentz, Cornelia Eckert, et al.

    Accurate modeling of intratumor heterogeneity presents a bottleneck against drug testing. Flexibility in a preclinical platform is also desirable to support assessment of different endpoints. We established the model system, OHC-NB1, from a bone marrow metastasis from a patient diagnosed with MYCN-amplified neuroblastoma and performed whole-exome sequencing on the source metastasis and the different models and passages during model development (monolayer cell line, 3D spheroid culture and subcutaneous xenograft tumors propagated in mice). OHC-NB1 harbors a MYCN amplification in double minutes, 1p deletion, 17q gain and diploid karyotype, which persisted in all models. A total of 80–540 single-nucleotide variants (SNVs) was detected in each sample, and comparisons between the source metastasis and models identified 34 of 80 somatic SNVs to be propagated in the models. Clonal reconstruction using the combined copy number and SNV data revealed marked clonal heterogeneity in the originating metastasis, with four clones being reflected in the model systems. The set of OHC-NB1 models represents 43% of somatic SNVs and 23% of the cellularity in the originating metastasis with varying clonal compositions, indicating that heterogeneity is partially preserved in our model system.


  • Automated Flow Cytometric MRD Assessment in Childhood Acute B‐ Lymphoblastic Leukemia Using Supervised Machine Learning

    by Michael Reiter, Markus Diem, Angela Schumich, Margarita Maurer‐Granofszky, Leonid Karawajew, Jorge G. Rossi, Richard Ratei, Stefanie Groeneveld‐Krentz, Elisa O. Sajaroff, Susanne Suhendra, et al.

    Minimal residual disease (MRD) as measured by multiparameter flow cytometry (FCM) is an independent and strong prognostic factor in B‐cell acute lymphoblastic leukemia (B‐ALL). However, reliable flow cytometric detection of MRD strongly depends on operator skills and expert knowledge. Hence, an objective, automated tool for reliable FCM‐MRD quantification, able to overcome the technical diversity and analytical subjectivity, would be most helpful. We developed a supervised machine learning approach using a combination of multiple Gaussian Mixture Models (GMM) as a parametric density model. The approach was used for finding the weights of a linear combination of multiple GMMs to represent new, “unseen” samples by an interpolation of stored samples. The experimental data set contained FCM‐MRD data of 337 bone marrow samples collected at day 15 of induction therapy in three different laboratories from pediatric patients with B‐ALL for which accurate, expert‐set gates existed. We compared MRD quantification by our proposed GMM approach to operator assessments, its performance on data from different laboratories, as well as to other state‐of‐the‐art automated read‐out methods. Our proposed GMM‐combination approach proved superior over support vector machines, deep neural networks, and a single GMM approach in terms of precision and average F 1‐scores. A high correlation of expert operator‐based and automated MRD assessment was achieved with reliable automated MRD quantification (F 1‐scores >0.5 in more than 95% of samples) in the clinically relevant range. Although best performance was found, if test and training samples were from the same system (i.e., flow cytometer and staining panel; lowest median F 1‐score 0.92), cross‐system performance remained high with a median F 1‐score above 0.85 in all settings. In conclusion, our proposed automated approach could potentially be used to assess FCM‐MRD in B‐ALL in an objective and standardized manner across different laboratories. © 2019 International Society for Advancement of Cytometry


  • Aneuploidy in children with relapsed B‐cell precursor acute lymphoblastic leukaemia: clinical importance of detecting a hypodiploid origin of relapse

    by Stefanie Groeneveld‐Krentz, Michael P. Schroeder, Michael Reiter, Malwine J. Pogodzinski, Helia J. Pimentel‐Gutiérrez, Renia Vagkopoulou, Jana Hof, Christiane Chen‐Santel, Karin Nebral, Jutta Bradtke, et al.

    Summary: Aneuploidy is common in paediatric B‐cell precursor acute lymphoblastic leukaemia (ALL). Specific subgroups, such as high hyperdiploidy (>50 chromosomes or DNA Index ≥1·16) and hypodiploidy (TP53 mutations. In these cases, array‐based allelotyping revealed a hypodiploid origin with absence of the hypodiploid founder clone (masked hypodiploidy). Collectively, patients with evident or masked hypodiploid relapses showed an extremely low event‐free survival rate of 9%. Importantly, the current relapse risk stratification did not identify cases with masked hypodiploidy as high‐risk patients, due to their favourable clinical presentation. In multivariate analysis, hypodiploidy proved to be an independent prognostic factor. This finding supports stratification of relapses with hypodiploid origin into high‐risk arms in future trials or allocation of patients to alternative treatment approaches.


  • Top Cited Papers

    IKZF1plusDefines a New Minimal Residual Disease–Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia

    by Martin Stanulla, Elif Dagdan, Marketa Zaliova, Anja Möricke, Chiara Palmi, Giovanni Cazzaniga, Cornelia Eckert, Geertruy Te Kronnie, Jean-Pierre Bourquin, Beat Bornhauser, et al.

    Purpose: Somatic deletions that affect the lymphoid transcription factor–coding gene IKZF1 have previously been reported as independently associated with a poor prognosis in pediatric B-cell precursor (BCP) acute lymphoblastic leukemia (ALL). We have now refined the prognostic strength of IKZF1 deletions by analyzing the effect of co-occurring deletions.Patients and Methods: The analysis involved 991 patients with BCP ALL treated in the Associazione Italiana Ematologia ed Oncologia Pediatrica–Berlin-Frankfurt-Muenster (AIEOP-BFM) ALL 2000 trial with complete information for copy number alterations of IKZF1, PAX5, ETV6, RB1, BTG1, EBF1, CDKN2A, CDKN2B, Xp22.33/Yp11.31 (PAR1 region; CRLF2, CSF2RA, and IL3RA), and ERG; replication of findings involved 417 patients from the same trial.Results: IKZF1 deletions that co-occurred with deletions in CDKN2A, CDKN2B, PAX5, or PAR1 in the absence of ERG deletion conferred the worst outcome and, consequently, were grouped as IKZF1plus. The IKZF1plusgroup comprised 6% of patients with BCP ALL, with a 5-year event-free survival of 53 ± 6% compared with 79 ± 5% in patients with IKZF1 deletion who did not fulfill the IKZF1plusdefinition and 87 ± 1% in patients who lacked an IKZF1 deletion ( P ≤ .001). Respective 5-year cumulative relapse incidence rates were 44 ± 6%, 11 ± 4%, and 10 ± 1% ( P ≤ .001). Results were confirmed in the replication cohort, and multivariable analyses demonstrated independence of IKZF1plus. The IKZF1plusprognostic effect differed dramatically in analyses stratified by minimal residual disease (MRD) levels after induction treatment: 5-year event-free survival for MRD standard-risk IKZF1pluspatients was 94 ± 5% versus 40 ± 10% in MRD intermediate- and 30 ± 14% in high-risk IKZF1pluspatients ( P ≤ .001). Corresponding 5-year cumulative incidence of relapse rates were 6 ± 6%, 60 ± 10%, and 60 ± 17% ( P ≤ .001).Conclusion: IKZF1plusdescribes a new MRD-dependent very-poor prognostic profile in BCP ALL. Because current AIEOP-BFM treatment is largely ineffective for MRD-positive IKZF1pluspatients, new experimental treatment approaches will be evaluated in our upcoming trial AIEOP-BFM ALL 2017.


  • Intragenic amplification of PAX5: a novel subgroup in B-cell precursor acute lymphoblastic leukemia?

    by Claire Schwab, Karin Nebral, Lucy Chilton, Cristina Leschi, Esmé Waanders, Judith M. Boer, Markéta Žaliová, Rosemary Sutton, Ingegerd Ivanov Öfverholm, Kentaro Ohki, et al.

    Key Points Intragenic PAX5 amplification defines a novel, relapse-prone subtype of B-cell precursor acute lymphoblastic leukemia with a poor outcome. Visual Abstract